The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
May 1st 2024
FDA approves label update for voclosporin (Lupkynis) in lupus nephritis, reflecting long-term AURORA data and new kidney function monitoring guidance.
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
Cases and Conversations™: Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
November 2024
Register Now!
EGPA: Highlighting the Patient Journey to Improve the Differential Diagnosis and Accelerate the Initiation of Guideline-Based Care
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical Consultations™: Optimal Approaches to Recognizing and Treating ANCA-Associated Vasculitis
View More
7 New Findings on Aspirin and NSAID Use
May 9th 2019It may have multi positive uses, but there are risks associated with using aspirin and other NSAIDs. In this slideshow, we highlight some recent findings that address how to calculate NSAID-related cardiovascular risk, a study that shows aspirin reduces cancer risk and another that says if taken appropriately, it can reduce the changes of major adverse cardiovascular events in diabetes patients.
7 New Findings on Aspirin and NSAID Use
May 9th 2019It may have multi positive uses, but there are risks associated with using aspirin and other NSAIDs. In this slideshow, we highlight some recent findings that address how to calculate NSAID-related cardiovascular risk, a study that shows aspirin reduces cancer risk and another that says if taken appropriately, it can reduce the changes of major adverse cardiovascular events in diabetes patients.
In Knee Osteoarthritis, Your Patient May Suffer From One of Four Depression Types
May 7th 2019Identifying the type of depression present in an individual with or at-risk for symptomatic knee osteoarthritis can help clinicians best target therapies to reduce pain and disability over time, according to a new study.
OARSI 2019: Osteoarthritis Treatments and More
May 3rd 2019Half of opioid prescriptions made today are not aligned with treatment guidelines, say researchers reporting this weekend in Toronto at the Osteoarthritis Research Society International (OARSI) World Congress on Osteoarthritis. In this slideshow, we highlight this and other presentations made at the meeting on Friday.
5 New Drug Approvals for Rheumatology Patients
April 26th 2019In rheumatology, there have been five new drug approvals in recent months for patients with rheumatoid arthritis, axial spondyloarthritis, plaque psoriasis, osteoporosis, among other conditions. Learn more about the new treatments and other drug news in this slideshow.
How can patient compliance be improved?
April 25th 2019Rheumatoid arthritis, psoriasis and psoriatic arthritis patients have consistently low levels of biologic adherence and persistence. How can patient compliance be improved? Lower out-of-pocket costs, utilize specialty pharmacies and improve patient education.
Febuxostat is Out for Gout Treatment
April 18th 2019In February, the Food and Drug Administration issued a boxed warning for the gout treatment febuxostat (Uloric, Takeda) citing a risk for cardiovascular disease. It was approved in 2009 for adult patients with gout. Learn more about this and the 2012 treatment guidelines for gout in this slideshow.